Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,884 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07463872Recruiting
Managing pancreatic cysts with AI and EUS data
This study uses artificial intelligence to look at EUS images and other information to better understand and manage pancreatic cysts. It aims to help doctors tell different types of cysts apart so they can choose the best treatment for you.
Wuhan, HubeiAges 18 years+ - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07479732RecruitingPhase 1/Phase 2
Apatinib with chemo for advanced osteosarcoma
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
BeijingAges 12–65 - NCT06012734RecruitingPhase 1
LB-100 plus Atezolizumab for metastatic colorectal cancer
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT07503717Recruiting
Brain scan surveillance in HER2-positive metastatic breast cancer
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
BeaumontAges 18 years+ - NCT07503756RecruitingPhase 2
JS212 Combination for Untreated Metastatic Colorectal Cancer
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT07536113Recruiting
Blood Test to Guide Second Colorectal Cancer Treatment
This study looks at whether a simple blood test can help doctors decide if you should receive a specific type of cancer drug again. The blood test looks for cancer DNA to predict if the drug will work for your advanced colorectal cancer.
Milan, ItaliaAges 18 years+ - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT07556640RecruitingPhase 2
Drug combination for stomach cancer with abdominal spread
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Shanghai, Huangpu DistrictAges 18 years+ - NCT07559760RecruitingPhase 2
New combination therapy for advanced colorectal cancer after first treatment
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Changchun, JilinAges 18–75 - NCT07563205Recruiting
Study of Chemotherapy and Amivantamab for Advanced Lung Cancer
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Aix-en-ProvenceAges 18 years+ - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07636200Recruiting
Managing Fear and Worry in Advanced Cancer
This study tests a new approach to help people with advanced cancer who feel significant fear about their cancer getting worse or coming back. The program uses writing and therapeutic techniques to help reduce this fear and related stress.
Aurora, ColoradoAges 18 years+ - NCT07670286Recruiting
Spotting early warning signs of pancreatic cancer wasting
This study checks if advanced computer analysis of your tumor and body can predict severe weight loss and muscle wasting (cachexia) from pancreatic cancer. If you join, you may help doctors find earlier warning signs to improve treatment.
BeijingAges 18 years+ - NCT07671339RecruitingPhase 1
Vaccine for pancreatic cancer with KRAS mutations
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,884 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.